Inside the research

Cytek Biosciences, Inc.

CTKB Research profile · latest available data

Price overview

$5.65

▼ -0.08 (-1.4%)

52w hi$5.88
52w lo$3.36
Vol1.49M
As of25 Sep 2026

The Verdict

Hold

Our score +0.01

Short+0.25
Medium+0.10
Long-0.64

computed 2026-09-27

Key fundamentals

Cytek Biosciences, Inc.

Healthcare · Medical Devices

Market cap$734.41M
Enterprise value$498.86M
Forward P/E80.71x
EV / EBITDA-12.55x
P / S (ttm)3.55x
Profit margin-39.0%
Return on equity-23.0%
Revenue growth+5.6%
Debt / equity8.22

Layer Breakdown

LayerRawContribution
Fundamental-0.16
Sector+0.08
Technical+0.20
Earnings+0.00
Sentiment-0.11

macro × 1.00 · 2026-09-27

Business overview

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

United States · cytekbio.com

Risk Metrics

Beta vs SPX1.24
Corr SPX0.30
Annual vol65.7%
Annual ret+26.3%
Sharpe0.40
Max DD-67.3%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-05Earnings Release, Exhibitsread
2026-07-15Officer / Director Changeread
2026-06-25Officer / Director Changeread
2026-06-16Shareholder Voteread
2026-06-02Officer / Director Changeread
2026-05-07Earnings Release, Exhibitsread
2026-02-26Earnings Release, Exhibitsread
2026-01-13Earnings Release, Exhibitsread
2025-11-05Earnings Release, Exhibitsread
2025-08-06Earnings Release, Exhibitsread
2025-06-24Shareholder Voteread
2025-05-08Earnings Release, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-06-12Yan MingDirector, Officer, CHIEF Gift135.89K—
2026-06-10Ball JackDirectorOption exercise43.97K—
2026-06-10Imper VeraDirectorOption exercise43.97K—
2026-06-10NEFF DEBORAH JDirectorOption exercise43.97K—
2026-06-10Holder MichaelDirectorOption exercise43.97K—
2026-05-18Holder MichaelDirectorOption exercise1.45K—
2026-05-18Chin RichardDirectorOption exercise6.11K—

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share96.0%
HHI4,430 (concentrated)

Top Holders

HolderValueShares
Millennium Management$41.37M9.34M
State Street Corp$11.37M2.57M
AQR Capital Management$3.61M813.97K
Citadel Advisors$3.20M721.47K
Renaissance Technologies$2.93M661.30K
Fidelity / FMR LLC$2.23M504.38K
Capital Research / Capital World$393.89K88.91K
T. Rowe Price Group$449101.20K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-124view
2026-08-0510-Qview
2026-08-058-Kview
2026-07-158-Kview
2026-06-303view
2026-06-258-Kview
2026-06-164view
2026-06-168-Kview
2026-06-124view
2026-06-124view
2026-06-124view
2026-06-123view
2026-06-124view
2026-06-124view
2026-06-124view

The Long Run

FY 2021–2025 · 5 years

LineLatestCAGRTrend
Revenue$201.49M+21.4%
Gross profit$111.11M+8.9%
Operating income-$40.38M-18.1%
Net income-$66.54M-6.4%
Cash from ops$5.28M+3.3%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$5.71$5.75$5.57$5.651.49M
Sep 24$5.64$5.83$5.48$5.731.60M
Sep 23$5.73$5.85$5.63$5.681.26M
Sep 22$5.29$5.84$5.26$5.713.78M
Sep 21$5.32$5.32$5.20$5.281.25M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →